ArticleMolecular cancer therapeutics2017

Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA).

Michael J Wagner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.